Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Winlet Pharmaceuticals (Pvt) Ltd.

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000874 117 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx117product presentations
G45generic molecules
DF6dosage-form groups
TA11therapeutic areas
PKR117current price records
REG92registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage99%
priced packs safely normalized per unit
Comparable-market coverage93%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixWinlet Pharmaceuticals (Pvt) Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/winlet-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026Anti-infectives49 · 42%Cardiovascular13 · 11%Vitamins, minerals & nutrition11 · 9%Gastrointestinal & hepatology11 · 9%CNS & mental health10 · 9%Pain & musculoskeletal10 · 9%Endocrine & metabolic6 · 5%Other therapeutic areas7 · 6%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioWinlet Pharmaceuticals (Pvt) Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/winlet-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026117presentationsTablet50 · 43%Suspension21 · 18%Capsule17 · 15%Injection14 · 12%Syrup13 · 11%Infusion2 · 2%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionWinlet Pharmaceuticals (Pvt) Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/winlet-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026109comparable productsBelow market median36 · 33%Near market median52 · 48%Above market median21 · 19%Company median price position-1.7%Lowest-price equivalents8Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsWinlet Pharmaceuticals (Pvt) Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/winlet-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026Nabiqasim Industries (Pvt) Ltd.,28 shared62% overlapPharmasol (Pvt) Ltd.27 shared60% overlapMediate Pharmaceutical Pvt Ltd26 shared58% overlapM/s. Genix Pharma (Pvt) Ltd.25 shared56% overlapCCL Pharmaceuticals (Pvt.) Ltd.25 shared56% overlapDe-Mont Research Laboratories (Pvt.…25 shared56% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives49 products · 42%
Cardiovascular13 products · 11%
Vitamins, minerals & nutrition11 products · 9%
Gastrointestinal & hepatology11 products · 9%
CNS & mental health10 products · 9%
Pain & musculoskeletal10 products · 9%
Endocrine & metabolic6 products · 5%
Hematology & thrombosis3 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Fluoroquinolone antibacterials11 products · 9%
Vitamins / minerals / hematinics11 products · 9%
Antifungals11 products · 9%
Analgesics / NSAIDs10 products · 9%
Macrolide antibacterials10 products · 9%
Calcium-channel blockers8 products · 7%
Antiemetics8 products · 7%
Antiepileptics6 products · 5%
Formulation footprint

Dosage forms

Tablet50 products
Suspension21 products
Capsule17 products
Injection14 products
Syrup13 products
Infusion2 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 OnsoftOndansetron 8presentations 4 mg, 4 mg/5 mL, 8 mg, 8 mg/4 mL · Tablet, Syrup, Injection #2 AntileptLevetiracetam 6presentations 100 mg/mL, 250 mg, 500 mg · Syrup, Tablet #3 MacrowinAzithromycin 6presentations 200 mg/5 mL, 250 mg, 500 mg · Suspension, Capsule, Tablet #4 ClarletClarithromycin 4presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Tablet #5 LinzoletLinezolid 4presentations 100 mg/5 mL, 600 mg, 600 mg/300 mL · Suspension, Tablet, Infusion #6 RicoletVoriconazole 4presentations 200 mg, 200 mg/5 mL, 50 mg · Tablet, Suspension
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median3633% of comparable products
Near market median52within ±5% of median
Above market median2119% of comparable products
Lowest-price equivalents8ties included
Company median price position -1.7% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Vincip 125 mg/5 mLCiprofloxacin · Dry suspension · 120ml PKR 2.02/mL-42.9% vs market median PTB 2 g + 0.25 gPiperacillin + tazobactam · Injection · 1 Vial PKR 418.37/vial/unit-41.2% vs market median PTB 4 g + 0.5 gPiperacillin + tazobactam · Injection · 1 Vial PKR 951.18/vial/unit-38.3% vs market median Ricolet 200 mg/5 mLVoriconazole · Dry suspension · 75ml PKR 25.68/mL-33.4% vs market median Ricolet 200 mg/5 mLVoriconazole · Dry suspension · 60ml PKR 27.07/mL-29.7% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 28shared generics Pharmasol (Pvt) Ltd.251 products · 101 generics 27shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 26shared generics M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 25shared generics CCL Pharmaceuticals (Pvt.) Ltd.243 products · 90 generics 25shared generics De-Mont Research Laboratories (Pvt.) Ltd.88 products · 44 generics 25shared generics
Regulatory & price activity

Observed database signals

Registration numbers92
Price-history records142
Products with price history23
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date1 Jul 2025
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

13 results
Intelligence filter: Therapeutic areaCardiovascular Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Amarus Amlodipine + Valsartan + Hydrochlorothiazide 5 mg + 12.5 mg + 160 mg Tablet 14'S 117810 PKR 155.42 PKR 11.10/tablet Near median
Amarus Amlodipine + Valsartan + Hydrochlorothiazide 10 mg + 12.5 mg + 160 mg Tablet 14'S 104831 PKR 286.03 PKR 20.43/tablet No comparator
Amarus Amlodipine + Valsartan + Hydrochlorothiazide 5 mg + 12.5 mg + 160 mg Tablet 28'S 117810 PKR 310.84 PKR 11.10/tablet Near median
Dtan 10 Amlodipine + Olmesartan 10 mg + 40 mg Tablet 20's 116519 PKR 1,606.17 PKR 80.31/tablet No comparator
Dtan 5 Amlodipine + Olmesartan 5 mg + 20 mg Tablet 20's 116518 PKR 967.91 PKR 48.40/tablet No comparator
Igner Irbesartan 300 mg Tablet 10'S 104820 PKR 706.27 PKR 70.63/tablet 8% above median
Laurent 10 Amlodipine + Valsartan 10 mg + 160 mg Tablet 14'S 107988 PKR 847.93 PKR 60.57/tablet 30% above median
Laurent 5 Amlodipine + Valsartan 5 mg + 160 mg Tablet 14'S 107989 PKR 722.62 PKR 51.62/tablet 18% above median
Laurent 5 Amlodipine + Valsartan 5 mg + 80 mg Tablet 14'S 107990 PKR 505.43 PKR 36.10/tablet 14% above median
Lobit Losartan 50 mg Tablet 20'S 104833 PKR 572.45 PKR 28.62/tablet 38% above median
Rothia Lisinopril + Hydrochlorothiazide 20 mg + 25 mg Tablet 14'S 117814 PKR 276.86 PKR 19.78/tablet 25% below median
Wintat Fluvastatin 40 mg Capsule 10'S 107993 PKR 410.10 PKR 41.01/capsule 13% above median
Wintat Fluvastatin 20 mg Capsule 10'S 107998 PKR 296.18 PKR 29.62/capsule 13% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.